Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions

Late stage breast cancer commonly metastasises to bone and patient survival averages 2–3 years following diagnosis of bone involvement. One of the most successful treatments for bone metastases is the bisphosphonate, zoledronic acid (ZOL). ZOL has been used in the advanced setting for many years whe...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Christopher N., Canuas-Landero, Victor, Theodoulou, Elizavet, Muthana, Munitta, Wilson, Caroline, Ottewell, Penelope
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516134/
https://www.ncbi.nlm.nih.gov/pubmed/32995253
http://dx.doi.org/10.1016/j.jbo.2020.100317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516134/
https://www.ncbi.nlm.nih.gov/pubmed/32995253
http://dx.doi.org/10.1016/j.jbo.2020.100317

Ejemplares similares